LIVE EVENT: The U.S. healthcare law rollout: Where do we stand?
WASHINGTON - Vice President Joe Biden will announce on Tuesday a new push to increase access to mental health services with $100 million in new government funding a year after the school shooting in Newtown, Connecticut, sparked a failed push for stronger gun control measures.
MARSEILLE/PARIS - The founder of a French breast implant company was sentenced to four years in prison on Tuesday for hiding the true nature of the sub-standard silicone used in implants sold to 300,000 women around the world.
COPENHAGEN - The United States Food and Drug Administration (FDA) on Tuesday published briefing documents about Grastek, an oral treatment for grass allergies ahead of a meeting by outside experts to discuss the drug.
- Merck & Co said it will advance its experimental Alzheimer's drug into late-stage trials among patients with mild to moderate disease, after an independent monitoring board reviewed its safety and recommended the trial continue to recruit patients.
- AbbVie Inc said a late-stage trial of its experimental hepatitis C therapy showed 96 percent of the patients who had previously failed to respond to treatment had no detectable levels of the virus in the blood after 12 weeks.
LONDON - U.S. Food and Drug Administration staff said on Tuesday they were wary about the benefits versus the risks of AstraZeneca and Bristol-Myers Squibb's new diabetes drug dapagliflozin.
COPENHAGEN - Novo Nordisk, the world's largest insulin maker, is facing a Danish police probe after it was reported by the financial watchdog for not disclosing at once that its big new product hope Tresiba had been refused U.S. approval.
WASHINGTON - The U.S. Supreme Court on Monday left intact a $142 million jury verdict against Pfizer Inc over the marketing of the epilepsy drug Neurontin.
COPENHAGEN - Novo Nordisk received European Union marketing authorization for its hemophilia drug NovoEight on November 13 2013, the Danish pharmaceutical company said on Monday.
- An advisory panel of medical experts on Monday voted to recommend that U.S. health regulators approve an experimental drug for ulcerative colitis and Crohn's disease developed by Takeda Pharmaceutical Co.
On Wednesday, December 4 at 10:30 a.m. watch live as experts assess where the U.S. stands in the healthcare law rollout and the resulting health policy implications. Presented by the forum at Harvard School of Public Health in collaboration with Reuters. Live Coverage